European Medical Solutions (FRA:AS0) EBIT per Share : €0.00 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is European Medical Solutions EBIT per Share?

European Medical Solutions's EBIT per Share for the six months ended in Dec. 2023 was €-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for European Medical Solutions's EBIT per Share or its related term are showing as below:

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of European Medical Solutions was 89.20% per year. The lowest was -59.40% per year. And the median was 7.85% per year.

FRA:AS0's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

European Medical Solutions's EBIT for the six months ended in Dec. 2023 was €-1.20 Mil.

European Medical Solutions EBIT per Share Historical Data

The historical data trend for European Medical Solutions's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Medical Solutions EBIT per Share Chart

European Medical Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.76

-0.04

European Medical Solutions Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

European Medical Solutions EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

European Medical Solutions's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.278	/	1489.607
=	-0.00

European Medical Solutions's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.199	/	1489.607
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00

European Medical Solutions (FRA:AS0) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

European Medical Solutions EBIT per Share Related Terms

Thank you for viewing the detailed overview of European Medical Solutions's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

European Medical Solutions (FRA:AS0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » European Medical Solutions (FRA:AS0) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ALIMG:Belgium

Address

7 Rue des Chasseurs Ardennais, Liege, BEL, 4031

Website

https://www.dms-imaging.com

DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

European Medical Solutions (FRA:AS0) Headlines

No Headlines